Veradermics has successfully raised $256 million in an upsized IPO, reflecting strong investor interest in its oral minoxidil therapy for hair loss. The company's shares surged over 120% on their first trading day, indicating robust market confidence in its lead program, often referred to as 'oral Rogaine'.
Investors show appetite for Veradermics’ extended-release oral minoxidil therapy, with Phase 3 trial currently underway. Medical aesthetics biotech Veradermics has raised around $256 million in an upsized initial public offering as it began trading on the New York Stock Exchange this week under the wonderfully-chosen ticker “MANE”. Shares in the company, priced at $17 in the IPO, jumped by more than 120% to over $38 in the first day of trading, with investors clearly excited by the prospects of its lead program – a hair-loss therapeutic dubbed “oral Rogaine”. Danny has worked in technology communications for more than 20 years, and has been writing about developments the longevity sector since 2019. With a keen interest in the transfer of technology to market, he focuses primarily on the companies working on cutting-edge solutions to aging and age-related diseases.
Original title: “Hair regrowth biotech raises $256m in ‘upsized’ IPO”